Statins in hypercholesterolaemia: A dose-specific meta-analysis of lipid changes in randomised, double blind trials

BMC Family Practice

Volumn 4, Issue , 2003, Pages 1-19

  Edwards, Jayne E ^a   Moore, R Andrew ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; HUMAN; HYPERCHOLESTEROLEMIA; LOW DRUG DOSE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 3042570661     PISSN: 14712296     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2296-4-18     Document Type: Review

References (28)

1. Anonymous: PACT - Cardiovascular prescribing. Prescription Pricing Authority 2002.
2. Shepherd J: The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. Am J Cardiol 1995, 76(9):113C-7C.
3. Anonymous: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344(8934):1383-9.
4. Sacks FM, Pfeffer MA, Moye LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996, 335(14):1001-9.
5. Primatesta P, Poulter NR: Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ 2000, 321(7272):1322-5.
6. Haq IU, Ramsay LE, Wallis E et al.: Population implications of lipid lowering for prevention of coronary heart disease: data from the 1995 Scottish health survey. Heart 2001, 86(3):289-95.
7. Harrop J, Donnelly R, Rowbottom A et al.: Improvements in total mortality and lipid levels after acute myocardial infarction in an English health district (1995-1999). Heart 2002, 87(5):428-31.
8. Kong SX et al.: Efficacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in the treatment of patients with hypercholesterolemia: A meta-analysis of clinical trials. Clin Ther 1997, 19:778-97.
9. Hebert PR, Gaziano JM, Chan KS, Hennekens CH: Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997, 278(4):313-21.
10. Law MR, Wald NJ, Rudnicka AR: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br Med J 2003, 326(7404):1423.
11. Schulz KF, Grimes DA, Altman DG, Hayes RJ: Blinding and exclusions after allocation in randomised controlled trials: survey of published parallel group trials in obstetrics and gynaecology. Br Med J 1996, 312:742-4.
12. Carroll D, Tramer M, McQuay H et al.: Randomization is important in studies with pain outcomes: Systematic review of transcutaneous electrical nerve stimulation in acute postoperative pain. Br J Anaesth 1996, 77(6):798-803.
13. Moher D, Cook DJ, Eastwood S et al.: Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 1999, 354:1896-1900.
14. Olsson A, Istad H, Luurila O et al.: Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 2002, 144:1044-1051.
15. Brown WV, Bays H, Hassman D et al.: Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial. Am Heart J 2002, 144:1036-1043.
16. Jadad AR, Moore RA, Carroll D et al.: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996, 17:1-12.
17. Gavaghan DJ, Moore RA, McQuay HJ: An evaluation of homogeneity tests in meta-analyses in pain using simulations of individual patient data. Pain 2000, 85:415-24.
18. Sterne JA, Gavaghan D, Egger M: Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000, 53(11):1119-29.
19. Tang JL, Liu JLY: Misleading funnel plot for detection of bias in meta-analysis. J Clin Epidemiol 2000, 53:477-84.
20. Pignone M, Phillips C, Mulrow C: Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. Br Med J 321 (7267):983-986. 2000 October 21
21. Khan KS, Daya S, Jadad AR: The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med 1996, 156:661-666.
22. Gotto AM Jr, Grundy SM: Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial Data. Issues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting. Circulation 1999, 99(8):E1-7.
23. Fenske TK: Lipid-lowering update 2001. Aggressive new goals. Can Fam Physician 2001, 47:303-9.
24. Pearson TA, Laurora I, Chu H, Kafonek S: The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000, 160(4):459-67.
25. Moore RA, Edwards J, McQuay H: Sildenafil (Viagra) for male erectile dysfunction: a meta-analysis of clinical trial reports. BMC Urol 2002, 2:6.
26. Moore RA, Gavaghan D, Tramer MR, Collins SL, McQuay HJ: Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998, 78(3):209-16.
27. Gaist D, Rodriguez LA, Huerta C, Hallas J, Sindrup SH: Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 2001, 12(5):565-9.
28. Gaist D, Jeppesen U, Andersen M et al.: Statins and risk of polyneuropathy: a case-control study. Neurology 2002, 58(9):1333-7.